Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies
Preprint
Abstract
Serological testing in the COVID-19 pandemic is mainly implemented to gain sero-epidemiological data, but can also retrospectively inform about suspected SARS-CoV-2 infection. We verified and applied a two-tiered testing strategy combining a SARS-CoV-2 receptor-binding domain (RBD)-specific lateral flow assay (LFA) with a nucleocapsid protein (NCP) IgG ELISA to assess seroconversion in n=7241 individuals. The majority had experienced symptoms consistent with COVID-19, but had no access to RT-PCR testing. Longitudinal follow-up in n=97 LFA+ individuals was performed up to 20 weeks after initial infection using NCP and spike protein S1 domain (S1) IgG ELISAs and a surrogate virus neutralization test (sVNT). Individuals reporting symptoms from January 2020 onwards showed seroconversion, as did a considerable proportion of asymptomatic individuals. Seroconversion for symptomatic and asymptomatic individuals was higher in an area with a known infection cluster compared to a low incidence area. Overall, 94% of individuals with a positive IgG result by LFA were confirmed by NCP ELISA. The proportion of ELISA-confirmed LFA results declined over time, in line with contracting NCP IgG titers during longitudinal follow-up. Neutralizing antibody activity was considerably more stable than S1 and NCP IgG titers, and both reach a plateau after approximately 100 days. The sVNT proved to be not only highly specific, but also more sensitive than the specificity-focussed two-tiered serology approach. Our results demonstrate the high specificity of two-tiered serology testing and highlight the sVNT used as a valuable tool to support modelling of SARS-CoV-2 transmission dynamics, complement molecular testing and provide relevant information to individuals.Keywords
All Related Versions
- Published version: Infectious Diseases, 53 (7), 498.
This publication has 65 references indexed in Scilit:
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- Covid-19: FDA approves use of convalescent plasma to treat critically ill patientsBMJ, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019Journal of Clinical Investigation, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- The Past, Present, and (Possible) Future of Serologic Testing for Lyme DiseaseJournal of Clinical Microbiology, 2016
- Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologymAbs, 2010
- Duration of Antibody Responses after Severe Acute Respiratory SyndromeEmerging Infectious Diseases, 2007
- Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike ProteinThe Journal of Immunology, 2006
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990
- The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E‐related strainsJournal of Medical Virology, 1984